1
|
Interferon beta therapy for multiple sclerosis (MS)
|
chr13:92884370
|
GPC5
|
CT
|
rs7987675
|
will likely not show increase response to interferon beta therapy in case of relapsed MS
|
2
|
Lumiracoxib-related liver toxicity
|
chr6:32305978
|
C6orf10
|
GT
|
rs3129900
|
increase in liver toxicity risk in response to lumiracoxib used to treat acute pain and osteoarthritic symptoms
|
3
|
Metformin Response
|
chr11:108239628
|
ATM-C11orf65
|
GG
|
rs4585
|
will respond better to Metformin
|
4
|
Ribavirin-induced anemia
|
chr20:3193842
|
ITPA
|
CA
|
rs1127354
|
greatly decreased odds of developing anemia when taking PEG-IFN/RBV
|
5
|
Statin induced myopathy
|
chr12:21331549
|
SLCO1B1
|
TT
|
rs4149056
|
typical dose of Simvastin will not increase myopathy risk
|
6
|
Floxacillin and liver toxicity
|
chr6:31431780
|
HCP5
|
TT
|
rs2395029
|
at typical dose liver toxicity is not expected in response to floxacillin
|
7
|
Beta-Blocker - heart failure risk
|
chr10:115805056
|
ADRB1
|
CC
|
rs1801253
|
Bucindolol is unlikely to reduce mortality odds in case of heart failure
|
8
|
Response to amitriptyline
|
chr7:87160561
|
ABCB1
|
AA
|
rs2032583
|
typical response to depression when treated with Elavil, Paxil, Effexor, or Celexa
|
9
|
Warfarin sensitivity
|
chr10:96702047
|
CYP2C9
|
CC
|
rs1799853
|
typical dose of warfarin does not increase risk of bleeding
|
chr10:96741053
|
CYP2C9
|
AA
|
rs1057910
|
chr16:31107689
|
VKORC1
|
CC
|
rs9923231
|
promoter
|
10 |
Fluorouracil toxicity |
chr1:97915613 |
DPYD |
CC |
rs3918290 |
No copies of the DPYD*2A mutation. May still be at risk for 5-FU toxicity due to other genetic or non-genetic factors |